Compile Data Set for Download or QSAR
Report error Found 25 Enz. Inhib. hit(s) with all data for entry = 9826
TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491842(US10975066, Example 5 | N-(1-(1H-indol-3- yl)hexan...)
Affinity DataIC50: 900nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491847(US10975066, Example 10 | N-(1-(1H-indol-3- yl)hexa...)
Affinity DataIC50: 1.00E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491846(US10975066, Example 9 | N-(1-(1H-indol-3- yl)hexan...)
Affinity DataIC50: 1.00E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491840(US10975066, Example 3 | N-(1-(1H-indol-3- yl)hexan...)
Affinity DataIC50: 1.10E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491843(US10975066, Example 6 | N-(1-(1H-indol-3- yl)hexan...)
Affinity DataIC50: 1.10E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491859(US10975066, Example 24)
Affinity DataIC50: 1.10E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491839(US10975066, Example 2 | N-(1-(1H-indol-3- yl)hexan...)
Affinity DataIC50: 1.20E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491853(US10975066, Example 16 | N-(2-(1H-indol-3- yl)ethy...)
Affinity DataIC50: 1.20E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491850(US10975066, Example 13 | N-(1-(1H-indol- 3-yl)hexa...)
Affinity DataIC50: 1.20E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491845(US10975066, Example 8 | N-(1-(1H-indol-3- yl)hexan...)
Affinity DataIC50: 1.20E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491844(US10975066, Example 7 | N-(1-(1H-indol-3- yl)hexan...)
Affinity DataIC50: 1.20E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491838(US10975066, Example 1 | N-(1-(1H-indol-3- yl)hexan...)
Affinity DataIC50: 1.40E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491854(US10975066, Example 18 | N-(1-(1H-indol-3- yl)hexa...)
Affinity DataIC50: 1.40E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491851(US10975066, Example 14 | N-(1-(1H-indol- 3-yl)-5-m...)
Affinity DataIC50: 1.40E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491858(US10975066, Example 23)
Affinity DataIC50: 1.40E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491841(US10975066, Example 4 | N-(1-(1H-indol-3- yl)hexan...)
Affinity DataIC50: 1.50E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491849(US10975066, Example 12 | N-(1-(1H-indol-3- yl)hexa...)
Affinity DataIC50: 1.50E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491848(US10975066, Example 11 | N-(1-(1H-indol-3- yl)hexa...)
Affinity DataIC50: 1.60E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491857(US10975066, Example 22)
Affinity DataIC50: 1.70E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491856(US10975066, Example 20 | N-(2-(1H-indol-3- yl)-1-p...)
Affinity DataIC50: 2.00E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491852(US10975066, Example 15 | N-(1-cyclopentyl- 2-(1H-i...)
Affinity DataIC50: 2.20E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491855(US10975066, Example 19 | N-(1-(1H-indol-3- yl)hexa...)
Affinity DataIC50: 2.40E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491862(US10975066, Example 66)
Affinity DataIC50: 2.40E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491861(US10975066, Example 64)
Affinity DataIC50: 4.60E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Ucb Biopharma

US Patent
LigandPNGBDBM491860(US10975066, Example 63)
Affinity DataIC50: 5.00E+3nMAssay Description:The fluorescence polarization assay tests the ability of compounds to inhibit the self-aggregation of α-synuclein peptide fragments. Peptides we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent